These conclusions highlight the potential of NGAL as an essential biomarker in the diagnosis of AKI, but due to its variability in platforms and cut-off points, difficulties are encountered in generalizing it for a more comprehensive use in clinical practice. Here, LCN2 is linked to acute kidney injury.